Health Care·Biotechnology·$3.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | -1.01 | N/A | +11.17% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | -1.01 | N/A | +11.17% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a sense of cautious optimism regarding the company's direction. They emphasized their commitment to innovation and future projects.
Management expressed optimism about future projects and ongoing research.
They highlighted the importance of innovation in driving growth.
Twist Bioscience's earnings report showed a smaller-than-expected loss per share, which led to a positive stock reaction, rising 11.18%. The company's focus on innovation and future projects suggests potential for growth, although no specific guidance was provided. Investors may view the earnings surprise as a sign of resilience in a challenging market.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
STERIS PLC
Aug 1, 2023